Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Downgrades InMode to Hold

Needham Downgrades InMode to Hold

Needham analyst Mike Matson downgrades InMode (NASDAQ:INMD) from Buy to Hold.

byBenzinga Newsdesk

February 17, 2023

1 minute read

Needham analyst Mike Matson downgrades InMode (NASDAQ:INMD) from Buy to Hold.

Guggenheim Initiates Coverage On Zscaler with Buy Rating, Announces Price Target of $233

By Benzinga Newsdesk

August 12, 6:43 AM

Guggenheim analyst John Difucci initiates coverage on Zscaler (NASDAQ:ZS) with a Buy rating and announces Price Target of $233.

Lantern Pharma Announces Publication In Clinical Cancer Research Highlighting The Enhanced Efficacy Of LP-184 In Glioblastoma

By Benzinga Newsdesk

October 3, 8:11 AM

Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple

LTRN

News
Tech

Lucid Secures Operating License To Begin EV Production In Saudi Arabia

By Anan Ashraf

September 23, 4:44 AM

California-headquartered EV maker Lucid Group has received an operating license to start car production in Saudi Arabia.

LCID

Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments

By Jelena Martinovic

December 9, 10:03 AM

Curaleaf Names Director Of Social Equity

CSE:TER

Needham Downgrades InMode to Hold

Related Posts

Guggenheim Initiates Coverage On Zscaler with Buy Rating, Announces Price Target of $233

Lantern Pharma Announces Publication In Clinical Cancer Research Highlighting The Enhanced Efficacy Of LP-184 In Glioblastoma

Lucid Secures Operating License To Begin EV Production In Saudi Arabia

Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments